{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:53:36Z","timestamp":1791204816712,"version":"4.1.0"},"reference-count":11,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND AND OBJECTIVES<\/jats:title>\n                    <jats:p>Clinical practice guidelines for pediatric obesity management allow for consideration of glucagon-like peptide-1 receptor agonists (GLP-1RA) in children ages 8\u201311. No study has documented secular trends in GLP-1RA prescribing in this group. We hypothesized that there would be a significant increase over time, particularly for children with more severe obesity, greater comorbidity burden, and less socioeconomic vulnerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This retrospective cross-sectional study of repeated annual cohorts from Epic Cosmos examined GLP-1RA prescriptions (Saxenda, Wegovy, Zepbound) for children (aged 8\u201311) without diabetes and with obesity from January 1, 2019 to June 17, 2026. A binomial logistic regression model for grouped data was performed to determine whether changes in the proportion of patients prescribed GLP-1RA over time were statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 3\u2009520\u2009531 children with obesity but without diabetes, 0.6% received a GLP-1RA prescription. Older children (11 years: 79.5\/10\u2009000 vs 8 years: 41.5\/10\u2009000), female children (75.9\/10\u2009000 vs 42.8\/10\u2009000), and children with less social vulnerability (low: 76.1\/10\u2009000 vs high: 49.2\/10\u2009000) were more likely to be prescribed GLP-1RAs. Children with obesity-related comorbidities were substantially more likely to be prescribed GLP-1RAs (188.9\/10\u2009000). Prevalent prescribing increased from 0.03% in 2019 to 9.3% in 2026, a 310-fold increase (P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In this cohort of &amp;gt;3.5 million children aged 8 to 11 with obesity and without diabetes, GLP-1RA prescribing increased sharply from 2019 to 2026 yet remained uncommon, reaching 0.6% of children. Clinicians appear to be reserving GLP-1RAs for those at greatest cardiometabolic risk. Prescriptions are more likely to go to those with less socioeconomic vulnerability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2026-077048","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:02:41Z","timestamp":1788480161000},"source":"Crossref","is-referenced-by-count":0,"title":["Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019\u20132026"],"prefix":"10.1542","volume":"158","author":[{"given":"Babak J.","family":"Orandi","sequence":"first","affiliation":[{"name":"1New York University Department of Surgery, New York, New York"},{"name":"2New York University Department of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhani S.","family":"Patel","sequence":"additional","affiliation":[{"name":"1New York University Department of Surgery, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Messito","sequence":"additional","affiliation":[{"name":"3New York University Department of Pediatrics, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal A.","family":"Mankowski","sequence":"additional","affiliation":[{"name":"1New York University Department of Surgery, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorry L.","family":"Segev","sequence":"additional","affiliation":[{"name":"1New York University Department of Surgery, New York, New York"},{"name":"4New York University Department of Population Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan B.","family":"Massie","sequence":"additional","affiliation":[{"name":"1New York University Department of Surgery, New York, New York"},{"name":"4New York University Department of Population Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"1","key":"2026100508180391500_r1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamapediatrics.2025.4291","article-title":"Prevalence of excess adiposity by body mass index category among US children and adolescents","volume":"180","author":"Chetty","year":"2026","journal-title":"JAMA Pediatr."},{"issue":"3","key":"2026100508180391500_r2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapediatrics.2025.5708","article-title":"GLP-1 receptor agonist prescriptions for adolescents with obesity and associated disparities","volume":"180","author":"Kim","year":"2026","journal-title":"JAMA Pediatr."},{"issue":"2","key":"2026100508180391500_r3","doi-asserted-by":"crossref","first-page":"e2022060640","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics."},{"issue":"22","key":"2026100508180391500_r4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med."},{"issue":"24","key":"2026100508180391500_r5","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med."},{"issue":"10511","key":"2026100508180391500_r6","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(25)01774-X","article-title":"Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"406","author":"Hannon","year":"2025","journal-title":"Lancet."},{"issue":"6","key":"2026100508180391500_r7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa2407379","article-title":"Liraglutide for children 6 to &lt;12 years of age with obesity - a randomized trial","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med."},{"key":"2026100508180391500_r8","year":"2025"},{"key":"2026100508180391500_r9","year":"2025"},{"issue":"10","key":"2026100508180391500_r10","first-page":"34","article-title":"Measuring community vulnerability to natural and anthropogenic hazards: The Centers for Disease Control and Prevention\u2019s Social Vulnerability Index","volume":"80","author":"Flanagan","year":"2018","journal-title":"J Environ Health."},{"issue":"1","key":"2026100508180391500_r11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1186\/s12889-023-16097-6","article-title":"Social vulnerability indices: a scoping review","volume":"23","author":"Mah","year":"2023","journal-title":"BMC Public Health."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-077048\/1954228\/pediatrics.2026077048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-077048\/1954228\/pediatrics.2026077048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:18:07Z","timestamp":1791202687000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/158\/4\/e2026077048\/208779\/Trends-in-GLP-1-Receptor-Agonist-Prescriptions-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,9,4]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2026-077048","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"e2026077048"}}